TY - JOUR
T1 - A six-week dose-response study of the ocular hypotensive effect of dorzolamide with a one-year extension
AU - Strahlman, E.
AU - Tipping, R.
AU - Vogel, R.
AU - Abrantes, P.
AU - Alm, A.
AU - Airaksinen, P. J.
AU - Barnebey, H.
AU - Borgeois, A.
AU - Cohen, J. S.
AU - Collignon-Brach, J.
AU - Cyrlin, M. N.
AU - Demailly, P.
AU - Ehinger, B.
AU - George, J. L.
AU - Greve, E.
AU - Gross, R. L.
AU - Higginbotham, E. J.
AU - Kass, M. A.
AU - Laibovitz, R. A.
PY - 1996
Y1 - 1996
N2 - PURPOSE: To investigate the efficacy and dose-response relationship of three concentrations (0.2%, 0.7%, and 2.0%) of dorzolamide hydrochloride in lowering elevated intraocular pressure (lOP) in patients during a six-week period and to evaluate the efficacy of 0.7% and 2.0% dorzolamide administered for an additional year. METHODS: This prospective, double-masked, randomized, placebo-controlled, multinational study enrolled 333 adults with open-angle glaucoma or ocular hypertension. During the six-week dose-response phase, patients were randomized to thrice-daily dosing of four treatments: 0.2%, 0.7%, or 2.0% dorzolamide or placebo (vehicle of dorzolamide). During a one-year extension, patients received 0.7% or 2.0% dorzolamide, and, if needed, 0.5% timolol twice daily for elevated IOP. RESULTS: In the dose-response phase, mean percent reduction of IOP (peak) was 16% to 18% for 2.0% and 0.7% dorzolamide and 4% to 7% for the placebo group, for a net reduction of IOP by dorzolamide of 11% to 14%. The 0.2% concentration of dorzolamide was not sufficiently active for further consideration. During the extension, dorzolamide maintained an adequate reduction of lOP in 55% (174 of 316) of patients. Throughout the study, the reduction in IOP was numerically greater for patients receiving 2.0% vs 0.7% dorzolamide. After 12 months of receiving dorzolamide, 20% to 28% of total carbonic anhydrase activity was observed. CONCLUSIONS: Topical dorzolamide used three times daily in concentrations of 0.7% or 2.0% lowered lOP and was generally well tolerated as monotherapy or in combination with 0.5% timolol.
AB - PURPOSE: To investigate the efficacy and dose-response relationship of three concentrations (0.2%, 0.7%, and 2.0%) of dorzolamide hydrochloride in lowering elevated intraocular pressure (lOP) in patients during a six-week period and to evaluate the efficacy of 0.7% and 2.0% dorzolamide administered for an additional year. METHODS: This prospective, double-masked, randomized, placebo-controlled, multinational study enrolled 333 adults with open-angle glaucoma or ocular hypertension. During the six-week dose-response phase, patients were randomized to thrice-daily dosing of four treatments: 0.2%, 0.7%, or 2.0% dorzolamide or placebo (vehicle of dorzolamide). During a one-year extension, patients received 0.7% or 2.0% dorzolamide, and, if needed, 0.5% timolol twice daily for elevated IOP. RESULTS: In the dose-response phase, mean percent reduction of IOP (peak) was 16% to 18% for 2.0% and 0.7% dorzolamide and 4% to 7% for the placebo group, for a net reduction of IOP by dorzolamide of 11% to 14%. The 0.2% concentration of dorzolamide was not sufficiently active for further consideration. During the extension, dorzolamide maintained an adequate reduction of lOP in 55% (174 of 316) of patients. Throughout the study, the reduction in IOP was numerically greater for patients receiving 2.0% vs 0.7% dorzolamide. After 12 months of receiving dorzolamide, 20% to 28% of total carbonic anhydrase activity was observed. CONCLUSIONS: Topical dorzolamide used three times daily in concentrations of 0.7% or 2.0% lowered lOP and was generally well tolerated as monotherapy or in combination with 0.5% timolol.
UR - http://www.scopus.com/inward/record.url?scp=9444268112&partnerID=8YFLogxK
U2 - 10.1016/S0002-9394(14)72009-4
DO - 10.1016/S0002-9394(14)72009-4
M3 - Article
C2 - 8694086
AN - SCOPUS:9444268112
SN - 0002-9394
VL - 122
SP - 183
EP - 194
JO - American journal of ophthalmology
JF - American journal of ophthalmology
IS - 2
ER -